BioRestorative Therapies
BRTX
13 hedge funds and large institutions have $531K invested in BioRestorative Therapies in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 4 closing their positions.
39% more capital inflows, than outflows
Capital inflows: $362K | Capital outflows: $261K
1.54% more ownership
Funds ownership: 6.63% → 8.17% (+1.5%)
0% more funds holding
Funds holding: 13 → 13 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$260K |
| 2 |
Renaissance Technologies
New York
|
+$38.3K |
| 3 |
Two Sigma Investments
New York
|
+$28K |
| 4 |
SG
StoneX Group
New York
|
+$16.9K |
| 5 |
Morgan Stanley
New York
|
+$15.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$154K |
| 2 |
Mariner
Overland Park,
Kansas
|
-$46.7K |
| 3 |
Two Sigma Advisers
New York
|
-$34.3K |
| 4 |
HRT Financial
New York
|
-$21K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$4.34K |
BRTX Hedge Fund Activity: Q1 2024 in Review
13 of the 6,963 institutional investors tracked by Wall St. Rank reported a position in BioRestorative Therapies (BRTX) for Q1 2024, worth a combined $531K — down 1.8% from $541K a quarter earlier.
Fund positioning in BRTX was balanced in Q1 2024: 4 funds opened new positions, 4 closed out, 3 added to existing stakes and 3 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $260K. The largest seller was Vanguard Group, cutting an estimated $154K.
- 13 institutional investors held BioRestorative Therapies (BRTX) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $531K of BioRestorative Therapies stock for Q1 2024, down 1.8% quarter-over-quarter.
- 4 funds opened new BioRestorative Therapies positions in Q1 2024 and 4 closed out, a net change of 0 holders.
- The largest BioRestorative Therapies buyer in Q1 2024 was Sabby Management, an estimated $260K added.
- The largest BioRestorative Therapies seller in Q1 2024 was Vanguard Group, an estimated $154K sold.
Based on aggregated 13F filings for Q1 2024.